Test Volume Drives up Neogenomics' Q1 Revenues 73 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Neogenomics today reported a 73 percent uptick in first-quarter revenues year over year as the number of tests performed increased 75 percent.

Revenues for the three months ended March 31 totaled $15.2 million, up from $8.8 million a year ago. The number of tests performed during the quarter increased to 26,932 from 15,396 a year ago.

A net loss of $893,000, or $.02 per share, a year ago was turned into a profit of $603,000, or $.01 per share, in Q1 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.